Fangyuan pharmaceutical invests another 200 million R & D new drugs, two first-class new drugs for patent application

The HPLC-PAD method of etimicin sulfate developed by Changzhou Fangyuan Pharmaceutical Co., Ltd and relevant units was not only included in Chinese Pharmacopoeia 2015, but also imitated by European and American Pharmacopoeia Over the years, Fangyuan pharmaceutical has continued to innovate in science and technology, with 8% of its annual sales being reinvested At present, two new drugs of category I and four generic drugs of category III under research are progressing smoothly Description = "the local file provided by the editor" sourcename = "local file" id = "324770" style = "border: 0px; vertical align: middle; width: 600px; height: 292px;" ALT = "" / > (data chart) at the engineering technology center of the company, Dr Liao xiongdeng, a Malaysian American, who is responsible for research and development, presented a transparent injection, abacus sulfate, to reporters on June 28 This is a highly difficult generic drug for the treatment of "superbugs." According to reports, the drug has been effective since it was launched in Japan in 1990, but because of its complex synthesis process, no domestic enterprise has been able to successfully copy it After nearly 10 years of development, Fangyuan pharmaceutical has finally got through the synthesis process of abecasin sulfate by the imported international R & D team, and is about to apply for clinical research The drug is expected to be put into production in 2018 "The reason why we insist on investment and innovation is to improve our core competitiveness." Ge Xiaohu, chairman of Fangyuan pharmaceutical, said The company integrates the internal and external advantageous resources of the enterprise, and constructs "one institute", "two stations" and "three centers", namely Jiangsu Institute of Microbiology, Chen Hongyuan academician workstation of Nanjing University, Wang Guangji academician workstation of China Pharmaceutical University, Jiangsu Engineering Technology Research Center of semi synthetic antibiotics, Jiangsu engineering technology research center of microbial pharmacy and Jiangsu enterprise technology center A number of foreign experts have been recruited to promote the in-depth integration of industry, University and research, guide scientific researchers to aim at the world's scientific frontier and jointly develop innovative drugs It is reported that during the 12th Five Year Plan period, the company has invested 111 million yuan in research and development, and another 200 million yuan will be invested in new drug research and development during the 13th Five Year Plan period Among them, two first-class new drugs, which are respectively used to treat leukemia and colon cancer, have applied for international and domestic patents, and are about to enter the preclinical research These new drugs will enable Fangyuan pharmaceutical to reach the end of the 13th five year plan, and form a pattern of multi varieties development with aminoglycoside antibiotics and etimicin as the main products It is estimated that the new sales will be nearly 1 billion yuan.